Digital Breast Tomosynthesis: ajronline.org


August 4, 20009 - Use of the combination of digital breast tomosynthesis and full-field digital mammography (FFDM) was associated with a 30 percent reduction in recall rate for cancer-free examinations that would have led to recall if FFDM had been used alone, reported a study published in American Roentgen Ray Society.

Researchers concluded that the use of digital breast tomosynthesis for breast imaging may result in a substantial decrease in recall rate.

The researchers' objective was to compare in a retrospective observer study the diagnostic performance of FFDM with that of digital breast tomosynthesis.
Eight experienced radiologists interpreted images from 125 selected examinations, 35 with verified findings of cancer and 90 with no finding of cancer. The four display conditions included FFDM alone, 11 low-dose projections, reconstructed digital breast tomosynthesis images, and a combined display mode of FFDM and digital breast tomosynthesis images. Observers rated examinations using the screening BI-RADS rating scale and the free-response receiver operating characteristic paradigm. Observer performance levels were measured as the proportion of examinations prompting recall of patients for further diagnostic evaluation. The results were presented in terms of true-positive fraction and false-positive fraction. Performance levels were compared among the acquisitions and reading modes. Time to view and interpret an examination also was evaluated.

Researchers found that a combined use of digital breast tomosynthesis and FFDM was associated with 30 percent reduction in recall rate for cancer-free examinations that would have led to recall if FFDM had been used alone. Use of digital breast tomosynthesis alone also tended to reduce recall rates, an average of 10 percent, although the observed decrease was not statistically significant (p = 0.09 for the participating radiologists). There was no convincing evidence that use of digital breast tomosynthesis alone or in combination with FFDM results in a substantial improvement in sensitivity.

For more information: www.ajronline.org/cgi/content/abstract/193/2/586


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
Subscribe Now